Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Fortress Biotech announced first quarter 2026 results showing a turnaround to $108.4 million net income attributable to common stockholders, driven by FDA approval of ZYCUBO® for Menkes disease and monetization of a $205 million Priority Review Voucher. The company strengthened its balance sheet by reducing debt and expanded its pipeline with the a…